Skip to main content
RACC logo

RACC · Research Alliance Corp III · Documents

Track RACC — free
$10.11 +0.04 (+0.40%)
Market Cap
$91.62M
Shares
9.10M
Volume · Nov 19 41.24K Avg daily vol (3M) 86.84K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Quarterly report New FY2026 Q3 10-Q filed Nov 16, 2026
2026
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Oak Hill Bio combination targets fourth quarter of 2026 close

Research Alliance Corporation III’s Oak Hill Bio combination is expected to close in the fourth quarter of 2026, supported by $55,000,000 of PIPE financing. Disclosure controls were ineffective as of September 30, 2026 due to a material weakness.

Read from the MD&A section
5 source passages
References to the “Company”, “us”, “our”, or “we” refer to Research Alliance Corporation III. However, in connection with the proposed business combination with OHB Pediatrics Ltd. (“Oak Hill Bio”), we filed a registration statement on Form S-4 (File No. 333-298537), which was declared effective by the Securities and Exchange Commission on November 4, 2026, and a related definitive proxy statement/prospectus pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on November 4, 2026 (the “Proxy Statement/Prospectus”). The OHBP Business Combination is expected to close in the fourth quarter of 2026, following the receipt of the requisite approvals of the Company’s shareholders and the fulfillment of other customary closing conditions. Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and the Company agreed to issue and sell to the PIPE Investors, on the date the Closing occurs (the “Closing Date”), (a) shares of New OHB Common Stock at $10.00 per share and/or (b) pre-funded warrants to purchase shares of New OHB Common Stock (the “Pre-Funded Warrants”), each to purchase one share of New OHB Common Stock, with a per share exercise price equal to $0.0001, at a purchase price per Pre-Funded Warrant equal to $10.00 less the exercise price (collectively, the “PIPE Financing”), for aggregate gross proceeds of $55,000,000. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective as we experienced difficulty in ensuring that the accounting for our accounts payable and accrued expenses is accurate and complete, including proper classification of the related expenses to deferred offering costs or operating expenses which we experienced and reported as a material weakness. Open the document at this passage
Oct 30
Registration statement S-4/A
Shareholders to Vote on $160,000,000 Oak Hill Bio Merger

Research Alliance Corporation III seeks shareholder approval at its November 24, 2026 meeting for a business combination with Oak Hill Bio, which has a $160,000,000 base equity value, plus a $55,000,000 PIPE financing.

Read from the first part of this long document
4 source passages
The extraordinary general meeting will be conducted via live webcast at 10:00 a.m., Eastern Time, on November 24, 2026, at the offices of Cooley LLP the Oak Hill Bio Shareholders will receive an aggregate of 16,000,000 shares of New OHB Common Stock in the Transactions upon the exchange of Oak Hill Bio Shares, based on the Base Equity Value of $160,000,000 divided by $10.00 per share. The aggregate gross proceeds to be received by RACC in connection with the PIPE Financing will be $55,000,000. Open the document at this passage
Sep 28
Registration statement S-4/A
Registration statement

Research Alliance Corporation III agreed to acquire OHB Pediatrics Ltd., issue 16,000,000 shares to its shareholders, and raise $55,000,000 through a PIPE financing; the combined company will move to Delaware and become Oak Hill Bio Inc.

Read from the first part of this long document
May 28
Current report 8-K Events of May 21
Other events AI summary on its way
Showing 1–12 of 12 documents
Key facts CIK 2118032 CUSIP G75226103 13F (30d) 18 filings 18 filers